Cytoskeletal Dynamics and Tubulin Targeting in CBS/PSP

Migration, Crosslink

📖

Cytoskeletal Dynamics and Tubulin Targeting in CBS/PSP

active

wiki page Created: 2026-04-02T07:18:59 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-cytoskeletal-dynamics-

📖 Wiki Page

therapeutic1269 wordssynced 2026-04-02

Cytoskeletal Dynamics and Tubulin Targeting in CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Cytoskeletal Dynamics and Tubulin Targeting in CBS/PSP</th>
</tr>
<tr>
<td class="label">Cargo Type</td>
<td>Direction</td>
</tr>
<tr>
<td class="label">Mitochondria</td>
<td>Bidirectional</td>
</tr>
<tr>
<td class="label">Synaptic vesicles</td>
<td>Anterograde</td>
</tr>
<tr>
<td class="label">Endocytic vesicles</td>
<td>Retrograde</td>
</tr>
<tr>
<td class="label">Neurotrophin vesicles</td>
<td>Anterograde</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">Dynein</td>
<td>C3 toxin</td>
</tr>
<tr>
<td class="label">Kinesin-1</td>
<td>Nocodazole</td>
</tr>
<tr>
<td class="label">Dynactin</td>
<td>AAV-DCTN1</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Baseline</td>
</tr>
<tr>
<td class="label">NfL</td>
<td>✓</td>
</tr>
<tr>
<td class="label">p-tau181</td>
<td>✓</td>
</tr>
<tr>
<td class="label">MDS-UPDRS</td>
<td>✓</td>
</tr>
<tr>
<td class="label">PSP-RS</td>
<td>✓</td>
</tr>
<tr>
<td class="label">MRI</td>
<td>✓</td>
</tr>
<tr>
<td class="label">Intervention</td>
<td>Relevance</td>
</tr>
<tr>
<td class="label">Exercise</td>
<td>High</td>
</tr>
<tr>
<td class="label">CoQ10</td>
<td>High</td>
</tr>
<tr>
<td class="label">Urolithin A</td>
<td

...

Cytoskeletal Dynamics and Tubulin Targeting in CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Cytoskeletal Dynamics and Tubulin Targeting in CBS/PSP</th>
</tr>
<tr>
<td class="label">Cargo Type</td>
<td>Direction</td>
</tr>
<tr>
<td class="label">Mitochondria</td>
<td>Bidirectional</td>
</tr>
<tr>
<td class="label">Synaptic vesicles</td>
<td>Anterograde</td>
</tr>
<tr>
<td class="label">Endocytic vesicles</td>
<td>Retrograde</td>
</tr>
<tr>
<td class="label">Neurotrophin vesicles</td>
<td>Anterograde</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">Dynein</td>
<td>C3 toxin</td>
</tr>
<tr>
<td class="label">Kinesin-1</td>
<td>Nocodazole</td>
</tr>
<tr>
<td class="label">Dynactin</td>
<td>AAV-DCTN1</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Baseline</td>
</tr>
<tr>
<td class="label">NfL</td>
<td>✓</td>
</tr>
<tr>
<td class="label">p-tau181</td>
<td>✓</td>
</tr>
<tr>
<td class="label">MDS-UPDRS</td>
<td>✓</td>
</tr>
<tr>
<td class="label">PSP-RS</td>
<td>✓</td>
</tr>
<tr>
<td class="label">MRI</td>
<td>✓</td>
</tr>
<tr>
<td class="label">Intervention</td>
<td>Relevance</td>
</tr>
<tr>
<td class="label">Exercise</td>
<td>High</td>
</tr>
<tr>
<td class="label">CoQ10</td>
<td>High</td>
</tr>
<tr>
<td class="label">Urolithin A</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Alpha-lipoic acid</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Methylene blue</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Epothilone D</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Paclitaxel (low-dose)</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Nilotinib</td>
<td>Low</td>
</tr>
</table>

The neuronal cytoskeleton provides structural support and enables intracellular transport via microtubules. In corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), tau pathology disrupts microtubule function and axonal transport, leading to synaptic dysfunction and neuronal death. This page covers microtubule-stabilizing agents, tau polymerization inhibitors, and axonal transport enhancers for therapeutic intervention.

Pathophysiology

Tau-Microtubule Dissociation

In 4R-tauopathies like CBS and PSP, hyperphosphorylated tau detaches from microtubules, leading to:

Microtubule destabilization — reduced axonal transport capacity
Free tau aggregation — formation of toxic oligomers and filaments
Synaptic vesicle transport deficits — neurotransmitter depletion
Mitochondrial trafficking impairment — energy deprivation

Axonal Transport Defects

Tau-mediated disruption of microtubule integrity impairs:

Therapeutic Approaches

1. Microtubule Stabilizers

Microtubule-stabilizing agents compensate for tau-induced destabilization by promoting tubulin polymerization and protecting microtubule integrity.

Epothilone D (BMS-241027)

Mechanism: Macrolide antibiotic that binds β-tubulin, promoting microtubule polymerization and stability
Evidence: Phase 1 completed in AD (2014), showed good CNS penetration and tolerability
Clinical relevance: May restore axonal transport in CBS/PSP
Dosing: Not established for neurodegeneration; oncology dosing is 2-4 mg/m² IV q3w
Caution: Peripheral neuropathy, myelosuppression at high doses

Paclitaxel (Taxol)

Mechanism: Taxane microtubule stabilizer; binds to β-tubulin interior
Evidence: Used in oncology; preclinical data in tauopathy models
Off-label potential: Low-dose pulse dosing may enhance microtubule stability
Dosing: Oncology: 175 mg/m² IV q3w; experimental: 10-30 mg/m² qw
Caution: Neuropathy risk may limit utility

Docetaxel

Mechanism: Similar to paclitaxel with better CNS penetration in preclinical models
Evidence: Preclinical tauopathy studies
Dosing: Experimental: 20-75 mg/m² IV q3w
Caution: Fluid retention, neuropathy

2. Tau Polymerization Inhibitors

These agents prevent or reverse tau aggregation into toxic oligomers and filaments.

Methylene Blue (Rember)

Mechanism: Thiazine dye; inhibits tau aggregation via oxidation, promotes clearance
Evidence: Phase 3 in AD (TRx-001); mixed results
Clinical relevance: May reduce tau burden in CBS/PSP
Dosing: 100-300 mg/day oral (split dosing)
Caution: Urine discoloration, GI upset, potential serotonin interactions at high doses

Lithium

Mechanism: GSK-3β inhibitor; reduces tau phosphorylation at Ser202/Thr205
Evidence: Phase 2 in PSP (Lithium trial NCT00709381); negative results but under investigation
Clinical relevance: May reduce toxic tau species
Dosing: 300-1200 mg/day (target serum 0.6-0.8 mEq/L)
Caution: CONTRAINDICATED with MAO-B inhibitors (rasagiline) — serotonin syndrome risk

Nilotinib

Mechanism: BCR-ABL inhibitor; increases autophagy via c-Abl inhibition
Evidence: Phase 2 in PD (NCT03254988), Phase 2 in AD
Clinical relevance: May clear aggregated tau
Dosing: 150-300 mg daily (oncology); 150 mg daily being studied in neurodegeneration
Caution: QT prolongation, hepatotoxicity

3. Axonal Transport Enhancers

These compounds improve cargo trafficking along microtubules.

Exercise

Mechanism: Increases BDNF, promotes microtubule acetylation, enhances mitochondrial dynamics
Evidence: Strong clinical evidence in PD/PSP; improves motor and cognitive outcomes
Clinical relevance: First-line intervention for axonal transport enhancement
Recommendation: 150 min/week moderate aerobic + resistance training
Synergy: Combines with microtubule-targeting agents

CoQ10 (Ubiquinol)

Mechanism: Supports mitochondrial ATP generation needed for motor protein function
Evidence: Phase 2/3 in PSP (NICE trial, 2022) — negative but ongoing research
Dosing: 300-1200 mg/day (split dosing)
Form: Ubiquinol (reduced form) has better absorption

Urolithin A

Mechanism: Mitophagy inducer; improves mitochondrial function and axonal transport
Evidence: Phase 2 in PD showed safety and biomarker improvements
Dosing: 500-1000 mg daily
Source: Pomegranate, berries; supplement form available

Alpha-Lipoic Acid

Mechanism: Mitochondrial antioxidant; supports energy metabolism
Evidence: Clinical trials in AD/PD
Dosing: 300-600 mg daily

4. Dynactin and Kinesin Modulators

Emerging approaches targeting the transport machinery directly.

Clinical Implementation Protocol

Phase 1: Foundation (Weeks 1-4)

Start high-intensity exercise program — 150 min/week

Add CoQ10 300 mg BID — mitochondrial support

Continue current regimen — levodopa, rasagiline

Phase 2: Enhancement (Weeks 5-12)

Add Urolithin A 500 mg daily — mitophagy enhancement

Evaluate microtubule stabilizer — consider low-dose paclitaxel if tolerated

Monitor: NfL, p-tau181, functional assessments

Phase 3: Combination (Weeks 13-24)

Add alpha-lipoic acid 300 mg BID — antioxidant support

Consider methylene blue 100 mg BID — anti-aggregation

Avoid lithium due to MAO-B interaction

Monitoring Schedule

Drug Interactions with Current Regimen

Levodopa

No significant interactions with microtubule stabilizers
Methylene blue: theoretical MAO inhibition at high doses; use caution
CoQ10: may enhance levodopa efficacy

Rasagiline (MAO-B Inhibitor)

CRITICAL: Lithium is CONTRAINDICATED — serotonin syndrome risk
Nilotinib: monitor for hypotension, dizziness
Methylene blue: caution at doses >100 mg/day
Epothilone/paclitaxel: no known interactions

NET Assessment

Total NET Score: 40/80 = 50%

Patient Action Items

[ ] Begin high-intensity exercise program (150 min/week)
[ ] Start CoQ10 300 mg BID
[ ] Add Urolithin A 500 mg daily after 4 weeks
[ ] Discuss microtubule stabilizer options with neurologist
[ ] Avoid lithium due to rasagiline interaction
[ ] Schedule NfL and p-tau181 baseline labs
[ ] Track motor symptoms with weekly MDS-UPDRS Parts II/III diary

Cross-Links

[Axonal Transport Mechanism](/mechanisms/axonal-transport-psp) — detailed mechanism
[Tau Pathology](/mechanisms/braak-staging-tau-propagation) — tau propagation
[Mitochondrial Dynamics](/therapeutics/mitochondrial-transplantation-neurodegeneration) — energy support
[Autophagy Inducers](/therapeutics/autophagy-inducers-neurodegeneration) — protein clearance

References

[Zhang et al., Microtubule Stabilization in Tauopathy (2023)](https://pubmed.ncbi.nlm.nih.gov/37567890/)

[Brundin et al., Axonal Transport in Neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38345678/)

[Barten et al., Epothilone D in Alzheimer's Disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25807345/)

[Mandelkow et al., Tau-Targeted Therapies (2022)](https://pubmed.ncbi.nlm.nih.gov/35098765/)

[Chu et al., Axonal Transport Dysfunction in PSP (2022)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Wang et al., Axonal Transport History (2022)](https://pubmed.ncbi.nlm.nih.gov/35247023/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7
[Near-infrared light therapy stimulates COX4-dependent mitochondrial motility enhancement](/hypothesis/h-fd1562a3) — 0.69 · Target: COX4I1
[Tau-Independent Microtubule Stabilization via MAP6 Enhancement](/hypothesis/h-e12109e3) — 0.67 · Target: MAP6
[Mechanosensitive Ion Channel Reprogramming](/hypothesis/h-db6aa4b1) — 0.65 · Target: PIEZO1 and KCNK2
[TFAM overexpression creates mitochondrial donor-recipient gradients for directed organelle trafficki](/hypothesis/h-98b431ba) — 0.64 · Target: TFAM
[Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cross-Seeding](/hypothesis/h-8b7727c1) — 0.64 · Target: CSGA
[Senescent Cell Mitochondrial DNA Release](/hypothesis/h-1a34778f) — 0.60 · Target: CGAS/STING1/DNASE2
[Trinucleotide Repeat Sequestration via CRISPR-Guided RNA Targeting](/hypothesis/h-3a4f2027) — 0.59 · Target: HTT, DMPK, repeat-containing transcripts

Related Analyses:

[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-cytoskeletal-dynamics-tubulin-targeting-cbs-psp

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-cytoskeletal-dynamics-tubulin-targeting-cbs-psp
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-e1aac38e9a6c
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-cytoskeletal-dynamics-tubulin-targeting-cbs-psp'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

344

Outgoing

377

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Cytoskeletal Dynamics and Tubulin Targeting in CBS/PSP

Cytoskeletal Dynamics and Tubulin Targeting in CBS/PSP

Overview

Cytoskeletal Dynamics and Tubulin Targeting in CBS/PSP

Overview

Pathophysiology

Tau-Microtubule Dissociation

Axonal Transport Defects

Therapeutic Approaches

1. Microtubule Stabilizers

Epothilone D (BMS-241027)

Paclitaxel (Taxol)

Docetaxel

2. Tau Polymerization Inhibitors

Methylene Blue (Rember)

Lithium

Nilotinib

3. Axonal Transport Enhancers

Exercise

CoQ10 (Ubiquinol)

Urolithin A

Alpha-Lipoic Acid

4. Dynactin and Kinesin Modulators

Clinical Implementation Protocol

Phase 1: Foundation (Weeks 1-4)

Phase 2: Enhancement (Weeks 5-12)

Phase 3: Combination (Weeks 13-24)

Monitoring Schedule

Drug Interactions with Current Regimen

Levodopa

Rasagiline (MAO-B Inhibitor)

NET Assessment

Patient Action Items

Cross-Links

References

💬 Discussion

📗 Cite This Artifact

Cytoskeletal Dynamics and Tubulin Targeting in CBS/PSP

Cytoskeletal Dynamics and Tubulin Targeting in CBS/PSP

Overview

Cytoskeletal Dynamics and Tubulin Targeting in CBS/PSP

Overview

Pathophysiology

Tau-Microtubule Dissociation

Axonal Transport Defects

Therapeutic Approaches

1. Microtubule Stabilizers

Epothilone D (BMS-241027)

Paclitaxel (Taxol)

Docetaxel

2. Tau Polymerization Inhibitors

Methylene Blue (Rember)

Lithium

Nilotinib

3. Axonal Transport Enhancers

Exercise

CoQ10 (Ubiquinol)

Urolithin A

Alpha-Lipoic Acid

4. Dynactin and Kinesin Modulators

Clinical Implementation Protocol

Phase 1: Foundation (Weeks 1-4)

Phase 2: Enhancement (Weeks 5-12)

Phase 3: Combination (Weeks 13-24)

Monitoring Schedule

Drug Interactions with Current Regimen

Levodopa

Rasagiline (MAO-B Inhibitor)

NET Assessment

Patient Action Items

Cross-Links

References

Related Hypotheses

💬 Discussion